Profile
| Metric | Value |
|---|---|
| Full Name | MoonLake Immunotherapeutics |
| Ticker | NASDAQ: MLTX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | moonlaketx.com |
| Employees | 100 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $11.29 | |
| Price, 1D Change | +1.07% | |
| Market Cap | $800M | |
| - | ||
| PE Ratio | - | |
| Beta | 0.65 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$1.89 | |
| EPS, 1Y Change | -158.09% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | HLXA | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.89 | |
| EPS Estimate | -$3.58 | |
| EPS Est. Change | -89.01% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $11.29 | |
| Price Target | - | $13.50 |
| Price Tgt. Change | - | +19.57% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.92 | -$0.73 | +20.33% | |
| -$1.72 | -$1.89 | -10.03% | |
| -$3.58 | N/A | -89.01% | |
| -$3.58 | N/A | -89.03% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -76.56% | |
| Price, 3Y | -9.82% | |
| Market Cap, 1Y | -73.68% | |
| Market Cap, 3Y | +63.91% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -158.09% | |
| EPS, 3Y | +72.35% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $11.29 | |
| SMA 200 | $34.50 | |
| SMA 200 vs Price | +205.55% | |
| SMA 50 | $12.70 | |
| SMA 50 vs Price | +12.45% | |
| Beta | 0.65 | |
| ATR | $0.75 | |
| 14-Day RSI | 33.66 | |
| 10-Day Volatility | 57.38% | |
| 1-Year Volatility | 109.34% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$1.89 | |
| Gross Profit | -$1.38M | |
| - | ||
| Operating Profit | -$143.09M | |
| - | ||
| Net Income | -$121.24M | |
| - | ||
| EBITDA | -$141.71M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.01 | |
| Current Ratio | 21.11 | |
| Quick Ratio | 21.11 | |
| - | ||
| - | ||
| Altman Z-Score | 19.01 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 2.77 | |
| EV/EBITDA | -2.19 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $446.82M | |
| Cash & Equivalents | $448.03M | |
| Total Assets | $477.93M | |
| Current Assets | $474.29M | |
| Total Liabilities | $24.54M | |
| Current Liabilities | $22.46M | |
| Total Debt | $2.83M | |
| Short Term Debt | $1.37M | |
| Accounts Payable | $0.00 |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $118.94M | |
| Operating Expenses | $141.71M | |
| Cost Of Goods Sold | $1.38M | |
| SG&A | $0.00 | |
| D&A | $1.38M | |
| Interest Expense | $0.00 | |
| Income Tax | $282.20K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$116.59M | |
| CFI | -$205.60M | |
| CFF | $51.31M | |
| Capex | $519.50K | |
| Free Cash Flow | -$117.11M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| HC Wainwright & Co. | → | |
| Wedbush | → | |
| Needham | → | |
| Guggenheim | → | |
| Citigroup | → | |
| RBC Capital | → | |
| BTIG | → |
Analyst sentiment
Institutional ownership
Screeners with MLTX
Data Sources & References
- MLTX Official Website www.moonlaketx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1821586/000182158625000022/0001821586-25-000022-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1821586/000182158625000006/0001821586-25-000006-index.htm
- MLTX Profile on Yahoo Finance finance.yahoo.com/quote/MLTX
- MLTX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/mltx
FAQ
What is the ticker symbol for MoonLake Immunotherapeutics?
The ticker symbol for MoonLake Immunotherapeutics is NASDAQ:MLTX
Does MoonLake Immunotherapeutics pay dividends?
No, MoonLake Immunotherapeutics does not pay dividends
What sector is MoonLake Immunotherapeutics in?
MoonLake Immunotherapeutics is in the Healthcare sector
What industry is MoonLake Immunotherapeutics in?
MoonLake Immunotherapeutics is in the Biotechnology industry
What country is MoonLake Immunotherapeutics based in?
MoonLake Immunotherapeutics is headquartered in Switzerland
When did MoonLake Immunotherapeutics go public?
MoonLake Immunotherapeutics initial public offering (IPO) was on October 20, 2020
Is MoonLake Immunotherapeutics in the S&P 500?
No, MoonLake Immunotherapeutics is not included in the S&P 500 index
Is MoonLake Immunotherapeutics in the NASDAQ 100?
No, MoonLake Immunotherapeutics is not included in the NASDAQ 100 index
Is MoonLake Immunotherapeutics in the Dow Jones?
No, MoonLake Immunotherapeutics is not included in the Dow Jones index
When was MoonLake Immunotherapeutics last earnings report?
MoonLake Immunotherapeutics's most recent earnings report was on November 5, 2025
When does MoonLake Immunotherapeutics report earnings?
The next expected earnings date for MoonLake Immunotherapeutics is February 26, 2026